Q-omics provides the consensus-scored ALG10B profile across patient tissues and cancer cell-line models. ALG10B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ALG10B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ALG10B RNA expression shows 20,990 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, HNSC, and UVM as cancer lineages where ALG10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG10B survival associations across molecular data types. ALG10B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG10B RNA expression–survival associations across cancer types. High ALG10B expression shows unfavorable associations in STAD and UVM, but favorable associations in BRCA, SCLC, KIRC and OV. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for ALG10B RNA expression.
This table summarizes ALG10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ALG10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG10B shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, CHOL, KIRP and LIHC. The HNSC box plot shows higher ALG10B RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with ALG10B in patient tissues and cancer cell lines. In patient samples, ALG10B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALG10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
